ClinicalTrials.gg
CompletedNCT00550407Updated Nov 23, 2016Results posted

An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients

A Phase 3 interventional study of lamotrigine and Placebo in Bipolar Disorder, sponsored by GlaxoSmithKline. Completed at 60 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-11-23.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
215
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies testing lamotrigine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Lamotrigine · Bipolar Disorder.

Enrollment
7th of 33
215 · median 72
Started
2007
with 2 others
Phase 3
11 of 33
none open now
Registered
19th of 33
by date
Lead sponsor
9 of 33
GlaxoSmithKline

Among the 33 studies testing lamotrigine in Bipolar Disorder, this one is the 7th largest by enrollment, is one of 3 that started in 2007, is one of 11 in phase 3, and was the 19th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 33 studies testing lamotrigine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About lamotrigine

Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing lamotrigine in Bipolar Disorder as a file.
02

Study summary

This study is planned to objectively assess the efficacy and safety of lamotrigine maintenance therapy after symptoms of mood episode had been stabilised by open-label treatment with lamotrigine alone or in combination with other psychotropic medication in patients with bipolar I disorder.

03

Conditions studied

  • Bipolar Disorder

Browse trials for

Keywords

  • Lamotrigine
  • Prevention of relapse or recurrence of a mood episode
  • Bipolar I disorder
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

At Screening Disease to be studied: Has a diagnosis of following disease as defined by criteria.

  • Bipolar I Disorder, most recent episode depressed(296.5x)
  • Bipolar I Disorder, most recent episode hypomanic(296.40)
  • Bipolar I Disorder, most recent episode manic(296.4x) The diagnosis of mood episode will be made with reference to Mini International Neuropsychiatric Interview: M.I.N.I, Japanese Version.

At Screening

The subject who has a diagnose of bipolar I disorder, most recent episode depressed (296.5x) must meet the following criteria:

  • Is currently experiencing a major depressive episode or has had a major depressive episode as defined by DSM-IV-TR criteria within 60 days of the screening visit and at least one additional major depressive episode and one manic or hypomanic episode, as defined by DSM-IV-TR criteria, within 3 years of enrolment. A well documented history of a mixed episode that meets DSM-IV-TR criteria may be counted as a previous episode.All subjects must have experienced at least one well-documented manic or mixed episode in the past.
  • Has a duration of the most recent/current depressive episode of at least 2 weeks but not longer than 12 months prior to enrolment.
  • The subject without current major depressive episode must have a major depressive episode within 60 days of screening and has depressive symptoms at screening or is under treatment for depressive symptoms, which can be confirmed by medical record, etc.
  • If the subject is currently experiencing a major depressive episode, the subject must have a minimum total score on the HAM-D (17-item scale) of 18 at the screening. This criterion will not apply to the subject with recent depressive episode.

At Screening

The subject who has a diagnose of bipolar I disorder, most recent episode hypomanic(296.4x) or bipolar I disorder, most recent episode manic(296.5x) must meet the following criteria:

  • Has experienced a recent manic or hypomanic episode (current or within 60 days of the Screening Visit) and has had at least one additional manic or hypomanic episode and one depressed episode, as defined by DSM-IV-TR criteria, within three years of enrolment. A well documented history of a mixed episode that meets DSM-IV-TR criteria may be counted as a previous episode. All subjects must have experienced at least one well-documented manic or mixed episode in the past.
  • Has a duration of the index manic episode of at least 1 week (unless hospitalised) or hypomanic episode of at least 4 days. In neither case should the index episode be more than 12 months in duration.
  • The subject current experiencing hypomania episode or without current episode must have a manic episode which can be confirmed by medical record, etc. The subject without current episode must have a episode within 60 days of screening and has manic or hypomanic symptomatology is under treatment for manic or hypomanic symptoms.
  • If the subject's index episode is subject initial manic mood event, subject must have a minimum score of 10 (moderate severity) on the first 11 items of the YMRS at the screening. A threshold YMRS score that indicates significant manic symptoms is not required for patients who previously experienced well-documented DSM-IV-level mania or when the index episode is hypomania or when a subject's index manic or hypomanic episode is documented to have occurred within 60 days of the screening Visit.

At Screening Age: Is at least 20 years of age (at the time of ). At Screening Sex: either sex. Female of will be eligible for inclusion in this study. However they have to have a negative pregnancy test at the screening visit, agree to further pregnancy testing at the time points determined in study assessments and procedures and practice one of the following methods of from the screening visit until the end of the follow-up examination.

  • Abstinence
  • Injectable progestogen
  • Implants of levonorgestrel
  • Intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP effectiveness criteria as stated in the product label
  • Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject
  • Double barrier method: condom or occlusive cap (diaphragm or cervical / vault caps) plus spermicidal agent (foam /gel / film / cream / suppository) At Screening In/Out patient: Either At Screening Informed consent: the subject capable of giving written informed consent. At Week 0 of First Phase (titration) If the subject is currently experiencing a major depressive episode, the subject must have a minimum total score at baseline on the HAM-D (17-item scale) of 18 at the start of First Phase. This criterion will not apply to the subject with recent depressive episode.

At Week 0 of First Phase (titration) If the subject's index episode is subject initial manic mood event, subject must have a minimum total score at baseline of 10 (moderate severity) on the first 11 items of the YMRS at the start of First Phase (titration). A threshold YMRS score that indicates significant manic symptoms is not required for patients who previously experienced well-documented DSM-IV-level mania or when the index episode is hypomania or when a subject's index manic or hypomanic episode is documented to have occurred within 60 days of the screening Visit.

At Week 0 of Second Phase (maintenance therapy) Each subject completing 8 to 16 weeks of open-label lamotrigine treatment in the First Phase must meet all of the following inclusion criteria to be eligible for entry into the Second Phase (maintenance therapy, randomization phase).

At Week 0 of Second Phase (maintenance therapy) Has no tolerability problem with lamotrigine at a minimum dosage of 100 mg/day during the final 2 weeks of the First Phase (titration).

At Week 0 of Second Phase (maintenance therapy) Has improved/stabilised during the First Phase (titration) as indicated by a CGI-S score of ≤3 (mildly ill). Once improved, the subject must also demonstrate sustained improvement by achieving a CGI-S score of ≤3 (mildly ill) for at least 4 consecutive weeks of treatment immediately prior to the Second Phase (maintenance therapy) (randomization).

At Week 0 of Second Phase (maintenance therapy) Has demonstrated adequate compliance with the study treatment in the First Phase (titration) (compliance rate: at least 70%).

At Week 0 of Second Phase (maintenance therapy) In/Out patient: Either

Exclusion criteria

Exclusion Criteria:

At Screening Has a diagnosis of rapid cycling and has had more than six mood episodes including depression, mania, hypomania or mixed, in the 12-month period prior to screening. Note: while 4 or more episodes in the past 12 months constitute rapid cycling up to six episodes in the past 12 months are allowed in this protocol.

At Screening Has a DSM-IV-TR diagnosis of bipolar I disorder, most recent episode mixed (296.6x).

At Screening Has a DSM-IV-TR diagnosis of Axis II which would suggest non-responsiveness to pharmacotherapy for bipolar disorder.

At Screening Has a DSM-IV-TR diagnosis of or has received treatment for major depressive disorder, panic disorder, obsessive-compulsive disorder, social phobia, bulimia nervosa, schizophrenia or schizoaffective disorder within 12 months of screening.

At Screening Has a history of substance (including alcohol and drugs) dependence within 12 months of screening or abuse within 1 month of screening according to DSM-IV-TR.

At Screening Patients whose mood episode is due to direct physiological effects of a general medical condition (for example, hypothyroidism, hyperthyroidism) At Screening Has a score of 3 or more on item of the HAM-D related to suicide or is at a high suicidal risk in the judgment of the investigator/sub-investigator.

At Screening Has a history of severe rash or rash due to anti-epileptic drugs. At Screening Patients with severe hepatic/renal/cardiac/pulmonary disorder or hematopoietic disorder. The severity refers to Grade 3 according to the Classification of the Severity of Adverse Experiences (PAB/SD Notification No. 80, dated 29 June 1992).

At Screening Patients have less than 5 years of remission history from (other than e.g. basal cell or squamous cell skin cancer, in-situ carcinoma of cervix or prostate CA in situ).

At Screening Patients with chronic hepatitis typeB and /or typeC which is positive of surface antigen (HBsAg)and/or antibody.

At Screening Has an acute or chronic illness likely to impair drug absorption, distribution, metabolism or excretion or has any unstable physical symptoms likely to require hospitalisation during participation in the study.

At Screening Female patients who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study.

At Screening Has a history or current diagnosis of epilepsy. At Screening Has a history of treatment with lamotrigine. At Screening Patients with a history of drug allergy to any ingredient of the test-drug. At Screening Has received an drug within 30 days of screening. At Screening Is morbidly obese ( [BMI] >40) BMI = body weight (kg)/height (m2).

At Screening Patients whom the investigator or sub-investigator considers ineligible for the study.

At Week 0 of First Phase (titration) Has a score of 3 or more on item of the HAM-D related to suicide or is at a high suicidal risk in the judgment of the investigator/sub-investigator and continues .to meet the criteria at the screening visit.

At Week 0 of Second Phase (maintenance therapy) Has signs or symptoms of psychosis. At Week 0 of Second Phase (maintenance therapy) Has a score of 3 or more on item of the HAM-D related to suicide or is at a high suicidal risk in the judgment of the investigator/sub-investigator.

At Week 0 of Second Phase (maintenance therapy) Has had a change in lamotrigine dosage during the final week of the First Phase (titration).

At Week 0 of Second Phase (maintenance therapy) Has a diagnosis of bipolar I disorder, most recent episode of depressed (296.5x) and has experienced manic, hypomanic or mixed symptoms; Has a diagnosis of bipolar I disorder, most recent episode hypomanic (296.40) or most recent episode manic (296.4x) and has experienced depressive symptoms, that require treatment during the First Phase (titration).

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
215 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    BW430C(lamotrigine)

    Drug: lamotrigine

Interventions

  • lamotrigine 100mg/day or 200mg/day

  • DrugPlacebo

    placebo once daily

06

What researchers measure

Primary outcomes

  1. Time to Withdrawal From Study

    The time from randomization to the time at which the participant was withdrawn from the Double-Blind Phase of the study for any reason was measured. No data are reported for the Lamotrigine group because of an incalculable confidence interval. See the outcome measure entitled "Number of Participants with a Withdrawal Event" for data regarding the number of participants who withdrew from the study.

    Time frame: Randomization to Study Withdrawal (up to Week 26)

Secondary outcomes

  1. Time to Intervention for Any Mood Episode (TIME)

    The TIME was defined as the time from entry into the Randomized Phase to the time of the first prescription of any additional pharmacotherapy or electroconvulsive therapy (ECT) determined by the Investigator to be necessary for treatment of a relapse or recurrence of depression or the recurrence of a manic, hypomanic, or mixed episode, whichever occurred first. Categorization as a manic, hypomanic, or mixed episode was left to the Investigator's discretion. See the outcome measure entitled "Number of Participants with Intervention for Any Mood Episode" for data related to TIME.

    Time frame: Randomization to Study Withdrawal (up to Week 26)

  2. Time to Intervention for Depressive Episode (TIDep)

    The TIDep was defined as the time from entry into the Randomized Phase to the time of the first prescription of any additional pharmacotherapy or ECT determined by the Investigator to be necessary for treatment of a relapse or recurrence of depression episode. No data are being presented for either treatment group. See the outcome measure entitled "Number of Participants with Intervention for Depressive Episode" for data related to TIDep.

    Time frame: Randomization to Study Withdrawal (up to Week 26)

  3. Time to Intervention for Manic, Hypomanic, or Mixed Episode (TIMan)

    The TIMan was defined as the time from entry into the Randomized Phase to the time of the first prescription of any additional pharmacotherapy or ECT determined by the Investigator to be necessary for treatment of the relapse or recurrence of a manic, hypomanic, or mixed episode. No data are being presented for either treatment group. See the outcome measure entitled "Number of Participants with Intervention for a Manic, Hypomanic, or Mixed Episode" for data related to TIMan.

    Time frame: Randomization to Study Withdrawal (up to Week 26)

  4. Clinical Global Impressions of Improvement (CGI-I) at Week 26/Withdrawal (Randomized Phase)

    The CGI-I is a 7-point scale that assessed the participant's global improvement compared to his/her condition at study entry whether or not, in the judgement of the Investigator, it was due entirely to drug treatment; 0=not assessed, 1= very much improved to 7= very much worse.

    Time frame: Week 26/Withdrawal

  5. Clinical Global Impressions of Improvement (CGI-I) at Week 16/Withdrawal (Preliminary Phase)

    The CGI-I is a 7-point scale that assessed the participant's global improvement compared to his/her condition at study entry whether or not, in the judgement of the Investigator, it was due entirely to drug treatment; 0=not assessed, 1= very much improved to 7= very much worse.

    Time frame: Week 16/Withdrawal

  6. Change From Baseline in Clinical Global Impressions of Severity (CGI-S) Scores at Week 26/Withdrawal (Randomized Phase)

    The CGI-S is a 7-point scale that assessed the participant's severity of illness based on the total clinical experience of the Investigator with this particular population; 0=not assessed, 1= normal, not at all ill to 7= among the most extremely ill participants. Change from baseline was calculated as the Week 26/Withdrawal value minus the baseline value (at the time of randomization).

    Time frame: Baseline and Week 26/Withdrawal

  7. Change From Baseline in Clinical Global Impressions of Severity (CGI-S) Scores at Week 16/Withdrawal (Preliminary Phase)

    The CGI-S is a 7-point scale that assessed the participant's severity of illness based on the total clinical experience of the Investigator with this particular population; 0=not assessed, 1= normal, not at all ill to 7= among the most extremely ill participants. Change from baseline was calculated as the Week 16/Withdrawal value minus the baseline value (at Week 0 of the Preliminary Phase).

    Time frame: Baseline and Week 16/Withdrawal

  8. Change From Baseline in Hamilton Rating Scale for Depression (HAMD-17) Scores at Week 26/Withdrawal (Randomized Phase)

    The HAMD-17 is a 17-item questionnaire that detects change and measures illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with the total HAMD-17 score ranging from 0 (not ill) to 52 (severely ill). Change from baseline was calculated as the Week 26/Withdrawal value minus the baseline value (at the time of randomization).

    Time frame: Baseline and Week 26/Withdrawal

  9. Change From Baseline in Hamilton Rating Scale for Depression (HAMD-17) Scores at Week 16/Withdrawal (Preliminary Phase)

    The HAMD-17 is a 17-item questionnaire that detects change and measures illness severity. Individual items are rated on a scale of 0-4, and 0-2, with the total HAMD-17 score ranging from 0 (not ill) to 52 (severely ill). Change from baseline was calculated as the Week 16/Withdrawal value minus the baseline value (at Week 0 of the Preliminary Phase).

    Time frame: Baseline and Week 16/Withdrawal

  10. Change From Baseline in Young Mania Rating Scale (YMRS) Total Scores at Week 26/Withdrawal (Randomized Phase)

    The YMRS is an 11-item questionnaire that detects change and measures illness severity. Individual items are rated on a scale of 0-8 and 0-4, with the total YMRS score ranging from 0 (not ill) to 60 (severely ill). Change from baseline was calculated as the Week 26/Withdrawal value minus the baseline value (at the time of randomization).

    Time frame: Baseline and Week 26/Withdrawal

  11. Change From Baseline in Young Mania Rating Scale (YMRS) Total Scores at Week 16/Withdrawal (Preliminary Phase)

    The YMRS is an 11-item questionnaire that detects change and measures illness severity. Individual items are rated on a scale of 0-8 and 0-4, with the total YMRS score ranging from 0 (not ill) to 60 (severely ill). Change from baseline was calculated as the Week 16/Withdrawal value minus the baseline value (at Week 0 of the Preliminary Phase).

    Time frame: Baseline and Week 16/Withdrawal

07

Results

Posted Jul 27, 2010

Participant flow

8-16 Week Preliminary (Open-Label) Phase
Participant flow — 8-16 Week Preliminary (Open-Label) Phase
MilestoneLamotrigine 25-200 mgPlaceboLamotrigine 200 mg
Started21500
Completed10300
Not completed11200
Withdrew: Adverse event5500
Withdrew: Lack of efficacy3900
Withdrew: Protocol violation100
Withdrew: Defined stopping criteria reached100
Withdrew: Lost to follow-up100
Withdrew: Investigator discretion800
Withdrew: Withdrew consent600
Withdrew: Continuation criteria not met100
26-Week Randomized Phase
Participant flow — 26-Week Randomized Phase
MilestoneLamotrigine 25-200 mgPlaceboLamotrigine 200 mg
Started05845
Completed01521
Not completed04324
Withdrew: Adverse event052
Withdrew: Lack of efficacy03619
Withdrew: Investigator discretion010
Withdrew: Withdrawal by subject013

Outcome measures

PrimaryTime to Withdrawal From Study

The time from randomization to the time at which the participant was withdrawn from the Double-Blind Phase of the study for any reason was measured. No data are reported for the Lamotrigine group because of an incalculable confidence interval. See the outcome measure entitled "Number of Participants with a Withdrawal Event" for data regarding the number of participants who withdrew from the study.

Time frame:
Randomization to Study Withdrawal (up to Week 26)
Reported as:
Median · days
Time to Withdrawal From Study
daysPlaceboLamotrigine 200 mg
Time to Withdrawal From Study67.5 (32.0 to 127.0)—
Statistical analysis
  • Placebo vs Lamotrigine 200 mg · Log Rank · p = 0.010
SecondaryTime to Intervention for Any Mood Episode (TIME)

The TIME was defined as the time from entry into the Randomized Phase to the time of the first prescription of any additional pharmacotherapy or electroconvulsive therapy (ECT) determined by the Investigator to be necessary for treatment of a relapse or recurrence of depression or the recurrence of a manic, hypomanic, or mixed episode, whichever occurred first. Categorization as a manic, hypomanic, or mixed episode was left to the Investigator's discretion. See the outcome measure entitled "Number of Participants with Intervention for Any Mood Episode" for data related to TIME.

Time frame:
Randomization to Study Withdrawal (up to Week 26)
Reported as:
Median · days
Time to Intervention for Any Mood Episode (TIME)
daysPlaceboLamotrigine 200 mg
Time to Intervention for Any Mood Episode (TIME)109.0 (43.0 to 141.0)—
SecondaryTime to Intervention for Depressive Episode (TIDep)

The TIDep was defined as the time from entry into the Randomized Phase to the time of the first prescription of any additional pharmacotherapy or ECT determined by the Investigator to be necessary for treatment of a relapse or recurrence of depression episode. No data are being presented for either treatment group. See the outcome measure entitled "Number of Participants with Intervention for Depressive Episode" for data related to TIDep.

Time frame:
Randomization to Study Withdrawal (up to Week 26)

No measurements were reported for this outcome.

SecondaryTime to Intervention for Manic, Hypomanic, or Mixed Episode (TIMan)

The TIMan was defined as the time from entry into the Randomized Phase to the time of the first prescription of any additional pharmacotherapy or ECT determined by the Investigator to be necessary for treatment of the relapse or recurrence of a manic, hypomanic, or mixed episode. No data are being presented for either treatment group. See the outcome measure entitled "Number of Participants with Intervention for a Manic, Hypomanic, or Mixed Episode" for data related to TIMan.

Time frame:
Randomization to Study Withdrawal (up to Week 26)

No measurements were reported for this outcome.

SecondaryClinical Global Impressions of Improvement (CGI-I) at Week 26/Withdrawal (Randomized Phase)

The CGI-I is a 7-point scale that assessed the participant's global improvement compared to his/her condition at study entry whether or not, in the judgement of the Investigator, it was due entirely to drug treatment; 0=not assessed, 1= very much improved to 7= very much worse.

Time frame:
Week 26/Withdrawal
Reported as:
Mean · points on a scale
Clinical Global Impressions of Improvement (CGI-I) at Week 26/Withdrawal (Randomized Phase)
points on a scalePlaceboLamotrigine 200 mg
Clinical Global Impressions of Improvement (CGI-I) at Week 26/Withdrawal (Randomized Phase)3.5 ± 1.502.4 ± 1.29
SecondaryClinical Global Impressions of Improvement (CGI-I) at Week 16/Withdrawal (Preliminary Phase)

The CGI-I is a 7-point scale that assessed the participant's global improvement compared to his/her condition at study entry whether or not, in the judgement of the Investigator, it was due entirely to drug treatment; 0=not assessed, 1= very much improved to 7= very much worse.

Time frame:
Week 16/Withdrawal
Reported as:
Mean · points on a scale
Clinical Global Impressions of Improvement (CGI-I) at Week 16/Withdrawal (Preliminary Phase)
points on a scaleLamotrigine 25-200 mg
Clinical Global Impressions of Improvement (CGI-I) at Week 16/Withdrawal (Preliminary Phase)3.1 ± 1.56
SecondaryChange From Baseline in Clinical Global Impressions of Severity (CGI-S) Scores at Week 26/Withdrawal (Randomized Phase)

The CGI-S is a 7-point scale that assessed the participant's severity of illness based on the total clinical experience of the Investigator with this particular population; 0=not assessed, 1= normal, not at all ill to 7= among the most extremely ill participants. Change from baseline was calculated as the Week 26/Withdrawal value minus the baseline value (at the time of randomization).

Time frame:
Baseline and Week 26/Withdrawal
Reported as:
Mean · points on a scale
Change From Baseline in Clinical Global Impressions of Severity (CGI-S) Scores at Week 26/Withdrawal (Randomized Phase)
points on a scalePlaceboLamotrigine 200 mg
Change From Baseline in Clinical Global Impressions of Severity (CGI-S) Scores at Week 26/Withdrawal (Randomized Phase)1.0 ± 1.190.4 ± 1.25
SecondaryChange From Baseline in Clinical Global Impressions of Severity (CGI-S) Scores at Week 16/Withdrawal (Preliminary Phase)

The CGI-S is a 7-point scale that assessed the participant's severity of illness based on the total clinical experience of the Investigator with this particular population; 0=not assessed, 1= normal, not at all ill to 7= among the most extremely ill participants. Change from baseline was calculated as the Week 16/Withdrawal value minus the baseline value (at Week 0 of the Preliminary Phase).

Time frame:
Baseline and Week 16/Withdrawal
Reported as:
Mean · points on a scale
Change From Baseline in Clinical Global Impressions of Severity (CGI-S) Scores at Week 16/Withdrawal (Preliminary Phase)
points on a scaleLamotrigine 25-200 mg
Change From Baseline in Clinical Global Impressions of Severity (CGI-S) Scores at Week 16/Withdrawal (Preliminary Phase)-0.7 ± 1.39
SecondaryChange From Baseline in Hamilton Rating Scale for Depression (HAMD-17) Scores at Week 26/Withdrawal (Randomized Phase)

The HAMD-17 is a 17-item questionnaire that detects change and measures illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with the total HAMD-17 score ranging from 0 (not ill) to 52 (severely ill). Change from baseline was calculated as the Week 26/Withdrawal value minus the baseline value (at the time of randomization).

Time frame:
Baseline and Week 26/Withdrawal
Reported as:
Mean · points on a scale
Change From Baseline in Hamilton Rating Scale for Depression (HAMD-17) Scores at Week 26/Withdrawal (Randomized Phase)
points on a scalePlaceboLamotrigine 200 mg
Change From Baseline in Hamilton Rating Scale for Depression (HAMD-17) Scores at Week 26/Withdrawal (Randomized Phase)5.4 ± 7.392.7 ± 7.77
SecondaryChange From Baseline in Hamilton Rating Scale for Depression (HAMD-17) Scores at Week 16/Withdrawal (Preliminary Phase)

The HAMD-17 is a 17-item questionnaire that detects change and measures illness severity. Individual items are rated on a scale of 0-4, and 0-2, with the total HAMD-17 score ranging from 0 (not ill) to 52 (severely ill). Change from baseline was calculated as the Week 16/Withdrawal value minus the baseline value (at Week 0 of the Preliminary Phase).

Time frame:
Baseline and Week 16/Withdrawal
Reported as:
Mean · points on a scale
Change From Baseline in Hamilton Rating Scale for Depression (HAMD-17) Scores at Week 16/Withdrawal (Preliminary Phase)
points on a scaleLamotrigine 25-200 mg
Change From Baseline in Hamilton Rating Scale for Depression (HAMD-17) Scores at Week 16/Withdrawal (Preliminary Phase)-4.1 ± 9.14
SecondaryChange From Baseline in Young Mania Rating Scale (YMRS) Total Scores at Week 26/Withdrawal (Randomized Phase)

The YMRS is an 11-item questionnaire that detects change and measures illness severity. Individual items are rated on a scale of 0-8 and 0-4, with the total YMRS score ranging from 0 (not ill) to 60 (severely ill). Change from baseline was calculated as the Week 26/Withdrawal value minus the baseline value (at the time of randomization).

Time frame:
Baseline and Week 26/Withdrawal
Reported as:
Mean · points on a scale
Change From Baseline in Young Mania Rating Scale (YMRS) Total Scores at Week 26/Withdrawal (Randomized Phase)
points on a scalePlaceboLamotrigine 200 mg
Change From Baseline in Young Mania Rating Scale (YMRS) Total Scores at Week 26/Withdrawal (Randomized Phase)2.2 ± 6.591.0 ± 5.67
SecondaryChange From Baseline in Young Mania Rating Scale (YMRS) Total Scores at Week 16/Withdrawal (Preliminary Phase)

The YMRS is an 11-item questionnaire that detects change and measures illness severity. Individual items are rated on a scale of 0-8 and 0-4, with the total YMRS score ranging from 0 (not ill) to 60 (severely ill). Change from baseline was calculated as the Week 16/Withdrawal value minus the baseline value (at Week 0 of the Preliminary Phase).

Time frame:
Baseline and Week 16/Withdrawal
Reported as:
Mean · points on a scale
Change From Baseline in Young Mania Rating Scale (YMRS) Total Scores at Week 16/Withdrawal (Preliminary Phase)
points on a scaleLamotrigine 25-200 mg
Change From Baseline in Young Mania Rating Scale (YMRS) Total Scores at Week 16/Withdrawal (Preliminary Phase)0.4 ± 10.45
Post-hocNumber of Participants With a Withdrawal Event

The number of participants who withdrew from the study was measured. This outcome measure was added post-hoc because no data are being reported for the Lamotrigine group regarding time to study withdrawal. See the primary outcome measure for time to study withdrawal data for the Placebo group. Data from participants who had not withdrawn were defined as censored.

Time frame:
Randomization to Study Withdrawal (up to Week 26)
Reported as:
Number · participants
Number of Participants With a Withdrawal Event
participantsPlaceboLamotrigine 200 mg
Withdrawal Event4324
Censored1521
Post-hocNumber of Participants With Intervention for Any Mood Episode

The number of participants with intervention for any mood episode was measured. The necessity of the intervention was determined by the Investigator's discretion. This outcome measure was added post-hoc because no data are being reported for the Lamotrigine group regarding time to intervention for any mood episode (TIME). See the outcome measure for TIME for data for the Placebo group. Data from participants who had not met TIME were defined as censored.

Time frame:
Randomization to Study Withdrawal (up to Week 26)
Reported as:
Number · participants
Number of Participants With Intervention for Any Mood Episode
participantsPlaceboLamotrigine 200 mg
Intervention Event3720
Censored2125
Post-hocNumber of Participants With Intervention for Depressive Episode

The number of participants with intervention for depressive episode was measured. The necessity of the intervention was determined by the Investigator's discretion. This outcome measure was added post-hoc because no data are being reported for the Placebo or Lamotrigine groups regarding time to intervention for depressive episode (TIDep). Data from participants who had not met TIDep were defined as censored.

Time frame:
Randomization to Study Withdrawal (up to Week 26)
Reported as:
Number · participants
Number of Participants With Intervention for Depressive Episode
participantsPlaceboLamotrigine 200 mg
Intervention Event2715
Censored3130
Post-hocNumber of Participants With Intervention for a Manic, Hypomanic, or Mixed Episode

The number of participants with intervention for a manic, hypomanic, or mixed episode was measured. The necessity of the intervention was determined by the Investigator's discretion. This outcome measure was added post-hoc because no data are being reported for the Placebo or Lamotrigine groups regarding time to intervention for manic, hypomanic, or mixed episode (TIMan). Data from participants who had not met TIMan were defined as censored.

Time frame:
Randomization to Study Withdrawal (up to Week 26)
Reported as:
Number · participants
Number of Participants With Intervention for a Manic, Hypomanic, or Mixed Episode
participantsPlaceboLamotrigine 200 mg
Intervention Event105
Censored4840

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lamotrigine 25-200 mg—14/215 (6.5%)84/215 (39.1%)
Placebo—1/58 (1.7%)17/58 (29.3%)
Lamotrigine 200 mg—1/45 (2.2%)15/45 (33.3%)
Most frequent serious events
Most frequent serious events
EventLamotrigine 25-200 mgPlaceboLamotrigine 200 mg
ManiaPsychiatric disorders8/2151/580/45
Upper limb fractureInjury, poisoning and procedural complications0/2150/581/45
Bipolar I disorderPsychiatric disorders2/2150/580/45
Affect labilityPsychiatric disorders1/2150/580/45
Suicide ideationPsychiatric disorders1/2150/580/45
Suicide attemptPsychiatric disorders1/2150/580/45
Altered state of consciousnessNervous system disorders1/2150/580/45
Drug eruptionSkin and subcutaneous tissue disorders1/2150/580/45
Completed suicidePsychiatric disorders1/2150/580/45
Most frequent other events
Most frequent other events
EventLamotrigine 25-200 mgPlaceboLamotrigine 200 mg
NasopharyngitisInfections and infestations49/21513/5811/45
HeadacheNervous system disorders22/2152/582/45
NauseaGastrointestinal disorders17/2152/580/45
DizzinessNervous system disorders16/2151/581/45
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/2150/583/45
ConstipationGastrointestinal disorders11/2153/582/45
DiarrhoeaGastrointestinal disorders11/2151/580/45

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboLamotrigine 200 mgTotal
Mean43.1 ± 12.6842.4 ± 11.7942.8 ± 12.25
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLamotrigine 200 mgTotal
Female312758
Male271845
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboLamotrigine 200 mgTotal
Asian-Japanese Heritage5844102
Asian-East Asian Heritage011
08

Study locations

60 sites
  • GSK Investigational Site
    Aichi, 470-1141, Japan
  • GSK Investigational Site
    Chiba, 260-8677, Japan
  • GSK Investigational Site
    Chiba, 272-8516, Japan
  • GSK Investigational Site
    Chiba, 289-2511, Japan
  • GSK Investigational Site
    Fukuoka, 800-0217, Japan
  • GSK Investigational Site
    Fukuoka, 802-0001, Japan
  • GSK Investigational Site
    Fukuoka, 802-0006, Japan
  • GSK Investigational Site
    Fukuoka, 807-8555, Japan
  • GSK Investigational Site
    Fukuoka, 810-0004, Japan
  • GSK Investigational Site
    Fukuoka, 812-8582, Japan
  • GSK Investigational Site
    Fukuoka, 814-0180, Japan
  • GSK Investigational Site
    Fukuoka, 815-0041, Japan
  • GSK Investigational Site
    Fukuoka, 830-0011, Japan
  • GSK Investigational Site
    Gunma, 375-0017, Japan
  • GSK Investigational Site
    Gunma, 377-0055, Japan
  • GSK Investigational Site
    Hiroshima, 734-8551, Japan
  • GSK Investigational Site
    Hiroshima, 737-0023, Japan
  • GSK Investigational Site
    Hokkaido, 002-8029, Japan
  • GSK Investigational Site
    Hokkaido, 060-0042, Japan
  • GSK Investigational Site
    Hokkaido, 060-8648, Japan
  • GSK Investigational Site
    Hokkaido, 064-0946, Japan
  • GSK Investigational Site
    Ibaraki, 311-3193, Japan
  • GSK Investigational Site
    Kanagawa, 216-8511, Japan
  • GSK Investigational Site
    Kanagawa, 221-0835, Japan
  • GSK Investigational Site
    Kanagawa, 224-8503, Japan
  • GSK Investigational Site
    Kanagawa, 225-0011, Japan
  • GSK Investigational Site
    Kanagawa, 231-0023, Japan
  • GSK Investigational Site
    Kanagawa, 238-0042, Japan
  • GSK Investigational Site
    Kumamoto, 861-8002, Japan
  • GSK Investigational Site
    Kyoto, 616-8421, Japan
  • GSK Investigational Site
    Mie, 510-8575, Japan
  • GSK Investigational Site
    Mie, 515-0044, Japan
  • GSK Investigational Site
    Nara, 634-8522, Japan
  • GSK Investigational Site
    Oita, 874-0011, Japan
  • GSK Investigational Site
    Oita, 879-5593, Japan
  • GSK Investigational Site
    Oita, 879-7501, Japan
  • GSK Investigational Site
    Okayama, 700-8558, Japan
  • GSK Investigational Site
    Osaka, 533-0005, Japan
  • GSK Investigational Site
    Osaka, 569-1041, Japan
  • GSK Investigational Site
    Osaka, 570-8507, Japan
  • GSK Investigational Site
    Osaka, 583-0884, Japan
  • GSK Investigational Site
    Osaka, 590-0018, Japan
  • GSK Investigational Site
    Saga, 842-0192, Japan
  • GSK Investigational Site
    Saitama, 332-0012, Japan
  • GSK Investigational Site
    Tokyo, 100-0006, Japan
  • GSK Investigational Site
    Tokyo, 113-8603, Japan
  • GSK Investigational Site
    Tokyo, 151-0053, Japan
  • GSK Investigational Site
    Tokyo, 152-0012, Japan
  • GSK Investigational Site
    Tokyo, 154-0004, Japan
  • GSK Investigational Site
    Tokyo, 154-0012, Japan
  • GSK Investigational Site
    Tokyo, 166-0003, Japan
  • GSK Investigational Site
    Tokyo, 170-0002, Japan
  • GSK Investigational Site
    Tokyo, 173-0037, Japan
  • GSK Investigational Site
    Tokyo, 180-0005, Japan
  • GSK Investigational Site
    Tokyo, 183-0042, Japan
  • GSK Investigational Site
    Tokyo, 187-8551, Japan
  • GSK Investigational Site
    Tokyo, 190-0023, Japan
  • GSK Investigational Site
    Tottori, 680-0011, Japan
  • GSK Investigational Site
    Tottori, 682-0023, Japan
  • GSK Investigational Site
    Yamagata, 999-2221, Japan
09

References and documents

Publications

  • Tsukasa Koyama, Teruhiko Higuchi, Shigeto Yamawaki, Shigenobu Kanba, Takeshi Terao, Atsuko Shinohara. Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. Japanese Journal of Clinical Psychiatry. 2011;40(3):369-383.
  • Hashimoto Y, Kotake K, Watanabe N, Fujiwara T, Sakamoto S. Lamotrigine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2021 Sep 15;9(9):CD013575. doi: 10.1002/14651858.CD013575.pub2. PubMed 34523118 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2007
First posted
Oct 29, 2007
Start
Nov 2007
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Jul 27, 2010
Last update
Nov 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00550407
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 29, 2007
Start date
Nov 2007
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Jul 27, 2010
Last update
Nov 23, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion